Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUAL Study of darunavir/ritonavir plus lamivudine versus continued triple therapy in virologically suppressed HIV infection
2014-000515-14Phase 4Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of darunavir, ritonavir, lamivudine, tenofovir disoproxil fumarate, emtricitabine and 1 more in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fundación SEIMC-GeSIDA. Primary endpoint: Primary efficacy endpoint. Started Apr 2014; status: completed.
02
Drugs
darunavirritonavirlamivudinetenofovir disoproxil fumarateemtricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2014-000515-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000515-14.